News

The agency has set a Prescription Drug User Fee Act (PDUFA) target date for mid-October this year. Dyanavel XR was developed using the company’s LiquiXR technology , which

In KTE-C19 therapy, patient’s T cells are genetically modified to express a CAR designed to target the antigen CD19, a protein expressed on the cell surface of B-cell

AU-011 includes Viral-like Nanoparticles that show highly selective targeting of solid tumors while leaving normal epithelium untouched. Uveal Melanoma is an aggressive form of cancer that develops in

Aspen’s products portfolio recorded revenue of A$106m and a direct contribution to profit before tax of A$26m for the year ended 30 June 2014. To be operated under

This is the company’s third product to receive this QIDP status after WCK 771 and WCK 2349 last year further strengthening its new drug discovery program. QIDP status

Primary immunodeficiencies are a group of disorders in which part of the body’s immune system is missing or does not function properly. The company is advancing the 20%

Under the deal, Eureka will apply its proprietary human sequence antibody libraries and its technology platform to discover antibodies recognizing intracellular proteins, which represent about 90% of cancer-specific

Highlights The agreement includes the creation of an incubator focused on potential treatments for major diseases such as breast cancer and lung fibrosis using the modulation of RHAMM.

ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma